Press Releases Ypsomed Group

Burgdorf - ln connection with allegations that the OptiClik pen could be infringing a US patent, Ypsomed has commissioned both an internal and an external expert opinion, both of which have concluded that the OptiClik pen device made by the company does not infringe the patent claims of Novo Nordisk. Ypsomed therefore considers the accusations made by Novo Nordisk to be unjustified. The patent infringement suit has no effect on production of the OptiClik pen or on the further expansion of production capacities at Ypsomed.

Press Releases Ypsomed Group

Burgdorf - Ypsomed has a general policy not to comment on stock price developments or rumours. Due to a enquiries from investors and press representatives, however, Ypsomed considers it important to make the following statements.

Press Releases Ypsomed Group

Burgdorf - In the 2004/05 business year Ypsomed achieved new highs in terms of sales, profit and investments. The Ypsomed Group's consolidated sales rose 21.7% to CHF 241.8 million. In the core business (pen systems, pen needles and Ypsotec) sales even increased by 42.8%. Particularly pleasing was a 157.8% rise in operating profit to CHF 47.5 million, representing an operating profit margin of 19.7%.

Burgdorf - Ypsomed AG in collaboration with Safety Syringes, Inc. has designed a reusable Autoinjector specifically for use with the UltraSafe Drug Delivery Systems by Safety Syringes, Inc.

Press Releases Ypsomed Group

Burgdorf - Ypsomed, the leading independent developer and manufacturer of custom-made injection pens for pharmaceutical and biotech companies, and one of the leading suppliers of pen needles, is focusing future investments on its core business.